Effects of risedronate alone or combined with vitamin K2on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 32, Issue 3, 2014, Pages 290-297

  Kasukawa, Yuji ^a   Miyakoshi, Naohisa ^a   Ebina, Toshihito ^b   Aizawa, Toshiaki ^b   Hongo, Michio ^a   Nozaka, Koji ^a   Ishikawa, Yoshinori ^a   Saito, Hidetomo ^a   Chida, Shuichi ^a   Shimada, Yoichi ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Orthopedic Surgery   (Japan)

Author keywords

Osteocalcin; Risedronate; Undercarboxylated osteocalcin (ucOC); Vertebral fracture

Indexed keywords

MENATETRENONE; OSTEOCALCIN; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID; FARNOQUINONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BRAIN INFARCTION; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; FEMALE; HEART DISEASE; HUMAN; INCIDENCE; LEG FRACTURE; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SPINE FRACTURE; SUICIDE ATTEMPT; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED STUDY; DRUG EFFECTS; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; HUMANS; INCIDENCE; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; SPINAL FRACTURES; VITAMIN K 2;

EID: 84904689495     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-013-0490-5     Document Type: Article

References (38)

1. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878-882 (Pubitemid 29126875)
2. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521
3. Lee YK, Jang S, Jang S, Lee HJ, Park C, Ha YC, Kim DY (2012) Mortality after vertebral fracture in Korea. Analysis of the National Claim Registry. Osteoporos Int 23:1859-1865
4. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5 mg once-daily dosage regimen. J Bone Miner Metab 24:405-413 (Pubitemid 44306178)
5. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517-523 (Pubitemid 34925645)
6. Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174-1181
7. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA (2011) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endoclinol Metab 96:1006-1014
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352 (Pubitemid 29483192)
9. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259 (Pubitemid 26147662)
10. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194 (Pubitemid 40863806)
11. Vestergaard P, Mosekilde L (2003) Fracture risk associated with smoking: a meta-analysis. J Intern Med 254:572-583 (Pubitemid 37521854)
12. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739 (Pubitemid 30174026)
13. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893-899 (Pubitemid 41103445)
14. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370:657-666 (Pubitemid 47285316)
15. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systemic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256-1261 (Pubitemid 43967576)
16. Tsugawa N, Shiraki M, Suhara Y, Kamao M, Ozaki R, Tanaka K, Okano T (2008) Low plasma phylloquinone concentration is associated with high incidence of vertebral fracture in Japanese women. J Bone Miner Metab 26:79-85 (Pubitemid 350308003)
17. Kaneki M, Hedges SJ, Hosoi T, Fujiwara S, Lyons A, Crean SJ, Ishida N, Nakagawa M, Takechi M, Sano Y, Mizuno Y, Hoshino S, Miyao M, Inoue S, Horiki K, Shiraki M, Ouchi Y, Orimo H (2001) Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip-fracture risk. Nutrition 17:315-321 (Pubitemid 32454984)
18. Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990-1047 (Pubitemid 19184853)
19. Suttie JW (1985) Vitamin K-dependent carboxylase. Annu Rev Biochem 54:459-477
20. Miki T, Nakatsuka K, Naka H, Kitatani K, Saito S, Masaki H, Tomiyoshi Y, Morii H, Nishizawa Y (2003) Vitamin K (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. J Bone Miner Metab 21:161-165 (Pubitemid 41184297)
21. Ozuru R, Sugimoto T, Yamaguchi T, Chihara K (2002) Time dependent effects of vitamin K2 (menatetrenone) on bone metabolism in postmenopausal women. Endocr J 49:363-370 (Pubitemid 34832310)
22. Tsugawa N, Shiraki M, Uenishi K, Ishida H, Minekami T, Kawamoto S, Mouri K, Okano T (2011) Association of vitamin K status with clinical fracture in elderly people. Osteoporos Jpn 19:244-245 (In Japanese)
23. Shiraki M, Aoki C, Yamazaki N, Ito Y, Tsugawa N, Suhara Y, Okano T (2007) Clinical assessment of undercarboxylated osteocalcin measurement in serum using an electrochemiluminescence immunoassay: establishments of cut-off values to determine vitamin K insufficiency in bone and to predict fracture leading to clinical use of vitamin K2. Iyaku Yakugaku 57:537-546 (In Japanese)
24. Aonuma H, Miyakoshi N, Hongo M, Kasukawa Y, Shimada Y (2009) Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption. Tohoku J Exp Med 218:201-205
25. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC II (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am JMed 101:488-501 (Pubitemid 126335969)
26. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H (1998) A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group. Endocr J 45:191-201 (Pubitemid 28259398)
27. Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H (2008) Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 26:260-264 (Pubitemid 351677843)
28. Shiraki M, Yamazaki Y, Shiraki Y, Hosoi T, Tsugawa N, Okano T (2010) High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment. J Bone Miner Metab 28:578-584
29. Uenishi K, Ishida H, Kamao M, Tsugawa N, Okano T, Shiraki M (2011) Development and evaluation of simple vitamin K intake questionnaire. Osteoporos Jpn 19:513-518 (In Japanese)
30. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
31. Fukunaga M, Nakamura T, Shiraki M, Kuroda T, Ohta H, Hosoi T, Orimo H (2004) Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab 22:104-110 (Pubitemid 38405038)
32. Murata K, Yano E (2002) Medical statistical for evidence-based medicine with SPBS user's guide. Nankodo, Tokyo
33. Vermeer C (1990) Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J 266:625-636
34. Hozuki T, Imai T, Tsuda E, Matsumura A, Yamamoto D, Toyoshima T, Suzuki S, Yamauchi R, Hayashi T, Hisahara S, Shimohama S (2010) Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K2 in corticosteroid-treated patients: a pilot study. Intern Med 49:371-376
35. Iwamoto J, Takeda T, Ichihara S (2003) Combined treatment with vitamin K2 and bisphosphonate in postmenopausal women with osteoporosis. Yonsei Med J 44:751-756 (Pubitemid 37408068)
36. Kasukawa Y, Miyakoshi N, Hongo M, Ishikawa Y, Noguchi H, Kamo K, Sasaki H, Murata K, Shimada Y (2010) Relationships between falls, spinal curvature, spinal mobility and back extensor strength in elderly people. J Bone Miner Metab 28:82-87
37. Horiuchi T, Kazama H, Araki A, Inoue J, Hosoi T, Onouchi T, Mizuno S, Ito H, Orimo H (2004) Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab 22:236-240 (Pubitemid 38660954)
38. Tanaka I, Hayakawa K, Oshima H (2009) Drug compliance of bisphosphonate in Japan: cohort study of bisphosphonate in a private clinic. Osteoporos Jpn 17:252-255 (In Japanese)